Every article, presentation, spotlight, and news item we've tagged to Therapies and Protocols.
Showing 25–44 of 44
Cleveland Clinic's awarded research uses redox biology—specifically NAD and NADH measurement—to assess metabolic viability of donor organs during the ischemic period before transplantation. This work translates longevity science concepts into actionable clinical tools for organ quality assessment and transplant outcomes.
MDLifespan and Cenegenics are expanding access to Therapeutic Plasma Exchange (TPE), a procedure that removes environmental toxins, microplastics, and heavy metals from circulation to reduce chronic inflammation. The partnership positions toxin clearance as a foundational longevity strategy, addressing inflammation that undermines cognitive, metabolic, and cardiovascular function.
GNC has introduced MitoQ Pure and MitoQ NAD+ Dual Action supplements targeting mitochondrial function and oxidative stress reduction. Both formulations address energy production and cellular aging through distinct mechanisms—direct antioxidant support and NAD+ level optimization.
Abinopharm released a white paper on AbinoNutra® NMN following FDA regulatory clarification confirming NMN's legality as a dietary supplement ingredient. A randomized, double-blind clinical trial demonstrated that 60 days of NMN supplementation at doses up to 900 mg increased blood NAD⁺ levels, improved physical performance and endurance, and showed favorable shifts in biological age markers with no serious adverse events.
A partnership between Science Corporation and Neurosoft Bioelectronics reduces brain-computer interface development costs from $75–100 million to under $5 million, accelerating clinical adoption of therapies for neurological conditions including epilepsy and tinnitus. For longevity practitioners, this infrastructure advancement enables faster restoration of neurological function and cognitive independence—essential dimensions of healthspan that outlive lifespan alone.
Epia Neuro has launched an implantable brain-computer interface designed to help stroke survivors translate neural intent into functional movement through assistive devices. The approach prioritizes practical restoration of independence in daily life rather than speculative enhancement, addressing a significant gap in post-stroke rehabilitation where functional disability persists across years or decades.
A single 30-minute sauna session at 73°C triggers a transient increase in circulating white blood cells, with neutrophils and lymphocytes rising immediately post-session and returning to baseline within 30 minutes. This mobilization effect suggests a mechanism through which regular sauna use may confer documented cardiovascular and longevity benefits.
An analysis of over 800,000 Danish women found no association between menopausal hormone therapy and increased all-cause mortality over 7-21 years of follow-up. This challenges the prevailing safety concerns that emerged from earlier studies and suggests the risk-benefit calculation for hormone therapy in perimenopausal women warrants reassessment based on individual clinical context.
Cognito Therapeutics presented clinical and biomarker data supporting Spectris, a non-invasive neurostimulation therapy using synchronized light and sound to modulate gamma frequency brain waves in Alzheimer's disease. Prior studies showed preserved brain structure, slowed cognitive decline, and reduced atrophy compared with controls, with favorable safety profiles and no amyloid-related imaging abnormalities.
Cognision360 consolidates neurobiomarker data collection and analysis for CNS clinical trials through automated workflows and standardized integration of EEG, sleep, eye tracking, wearables, and cognitive assessments. The platform addresses fragmentation in multi-site studies and accelerates regulatory pathways by improving data integrity and reducing manual processing errors.
A Phase II clinical trial of XS411, a stem cell therapy designed to replace dopamine-producing neurons lost in Parkinson's disease, has advanced based on encouraging Phase I results showing improved motor function and no adverse events. The approach represents a shift from symptomatic management toward cellular repair, potentially restoring function rather than merely masking decline.
Aspen Neuroscience's autologous cell therapy for Parkinson's disease demonstrates early restoration of motor function and quality of life through transplantation of patient-derived dopamine-producing neurons into the brain. This represents a shift from symptomatic management toward biological reconstruction of damaged neural tissue.
Beacon Biosignals raised $97 million in Series B extension funding to advance at-home EEG technology and AI-driven neural analytics for diagnostic and clinical applications. The capital supports commercialization of FDA-cleared wearable technology that captures real-world brain activity data for precision medicine.
Blue light exposure triggers excessive mitochondrial fragmentation in retinal cells through a specific protein (Drp1), driving cellular changes associated with age-related macular degeneration. Blocking this fragmentation restores mitochondrial function and reverses the pathological transformation in both cell cultures and animal models.
A comprehensive market analysis catalogs over 80 RNA therapy companies and 100+ drug candidates across multiple modalities—mRNA, siRNA, antisense oligonucleotides, aptamers, and CRISPR approaches. The research examines development stages, delivery mechanisms, and commercial landscapes, with established players like Novartis and Arrowhead Pharmaceuticals advancing candidates across multiple therapeutic areas.
Cortechs.ai and Siemens Healthineers have partnered to integrate NeuroQuant, an FDA-cleared AI neuroimaging tool, into clinical workflows for automated brain lesion tracking and volumetric quantification. This expands clinician access to objective, longitudinal brain imaging data for monitoring neurological disease progression and treatment response, including anti-amyloid therapies for Alzheimer's disease.
Insilico Medicine and Tenacia Biotechnology are expanding their AI-driven collaboration to design small-molecule therapies for central nervous system disorders, with a focus on blood-brain barrier penetration. This partnership demonstrates how generative AI can accelerate drug discovery for neurological conditions, including a candidate targeting NLRP3 inflammation that has cleared FDA review for Parkinson's disease trials.
A 30-minute sauna session at 73°C triggers acute mobilization of circulating white blood cells across all major subtypes—neutrophils, lymphocytes, and monocytes—without selective recruitment of specific immune populations. This transient spike in immune surveillance capacity may represent a physiological mechanism underlying the epidemiological associations between regular sauna use and reduced cardiovascular disease, stroke, dementia, and all-cause mortality risk.
A correction to prior research on photobiomodulation's mechanism in Alzheimer's disease clarifies the molecular pathway by which light exposure modulates neuroinflammatory signaling. The finding reinforces the relevance of non-pharmacological interventions targeting neurodegeneration at the cellular level.
NeuroTherapia's oral Alzheimer's candidate NTRX-07 completed Phase 2a with safety clearance and early signals suggesting effects on neuroinflammation, the chronic immune dysregulation increasingly recognized as a major driver of cognitive decline. The drug targets brain inflammation rather than amyloid alone, representing a shift toward multi-system disease understanding.
